Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$3.44 - $6.37 $4.54 Million - $8.42 Million
-1,321,200 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$1.2 - $4.52 $833,040 - $3.14 Million
694,200 Added 110.72%
1,321,200 $3.59 Million
Q2 2019

Aug 14, 2019

BUY
$3.23 - $5.41 $752,590 - $1.26 Million
233,000 Added 59.14%
627,000 $2.52 Million
Q3 2018

Nov 14, 2018

BUY
$8.27 - $13.56 $3.26 Million - $5.34 Million
394,000 New
394,000 $5.34 Million

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $98M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Capital International Investors Portfolio

Follow Capital International Investors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Investors with notifications on news.